Chief Executive Officer
Eliot joined Immunocore as Chief Executive Officer in January 2015. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and previously served as Chief Executive Officer of Creabilis from 2010. Prior to that he was Chief Executive Officer of US biotechnology company, Solace Pharmaceuticals Inc. Other previous roles include Head of EU Development and Operations for the EU and Asia at Pfizer. Eliot is currently Chairman of the MedCity project that promotes the Life Sciences in the “Golden Triangle”. He is an Honorary Visiting Professor of the Pharmacology and Physiology Department at the University of Liverpool and is a Board member of OSCHR (Office for Strategic Coordination of Health Research). He holds a PhD in neurophysiology from University of Liverpool and an MBA from Henley Management College.
Chief Scientific Officer
Bent co-founded Immunocore in 2008 and has served as Chief Scientific Officer and Executive Board Member since that time. He is also scientific co-founder of Adaptimmune Ltd, where he provides strategic and advisory input as well as oversight of research programmes. He was previously Chief Scientific Officer of Avidex, a company he founded in 1999 as a spin-out from the University of Oxford to develop novel T cell receptor-based drugs. Bent was head of the Immune Receptor Group at the Institute of Molecular Medicine (IMM) in Oxford from 1993 to July 2000. Prior to this, he was a Senior Research Fellow of the Danish Natural Research Council, Aarhus, Denmark, and undertook post-doctoral research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge. Bent has authored numerous scientific papers and is considered a world expert in the field of T cell receptor immunology. In 2015, he was recognised for his contribution to medical science with an election to the Fellowship of the Academy of Medical Sciences.
Chief Business Officer
Eva-Lotta joined Immunocore as Chief Business Officer in May 2013. She has over 25 years of business development experience from the biotechnology and life science industry in both private and public companies, and is an elected member of the BioIndustry Association (BIA) Board of Directors. She is also on the Board of Targovax ASA. Eva-Lotta was previously at Ablynx NV, where she served as Chief Business Officer from 2006. Prior to Ablynx, Eva-Lotta served as Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals and before that held senior positions at Oxford Asymmetry International plc (now part of Evotec) and Oxford GlycoSystems. She received her degree in microbiology from the University of Stockholm.
Chief Financial Officer
Paul joined Immunocore as Chief Financial Officer in January 2017. He has over 25 years’ experience in the life sciences and telecommunications sectors. Mr Fry spent more than 25 years at GlaxoSmithKline (GSK), serving in a number of roles including as Chief Financial Officer for GSK’s Italian Pharmaceutical business and as Head of Global Drug Discovery Finance in R&D. More recently he oversaw the financial aspects of GSK’s recent multibillion dollar 3-part transaction with Novartis. Prior to joining Immunocore Paul served as Director of Global Finance Operations at Vodafone plc, where he was responsible for the global delivery of Vodafone’s core financial processes as well as large transformation projects and programmes. He holds a BA Hons degree in Philosophy, Politics and Economics (PPE) from the University of Oxford.
Chief Medical Officer
Chris joined Immunocore as Chief Medical Officer in April 2015. She has extensive experience in oncology drug development, with expertise in both clinical development and translational medicine. Prior to joining Immunocore Chris led two early development programmes at Novartis in checkpoint inhibition and PI3 kinase inhibition. She has also served as International Project Team Leader at Morphotek Inc., the monoclonal antibody company acquired by Eisai Co. Ltd in 2007, where she led the early clinical development team responsible for monoclonal antibody development against novel targets. Chris graduated with an M.D. and Ph.D from the University of Pennsylvania, where she studied patient responses to tumour antigens with Dr Robert Vonderheide in the division of Translational Research under the direction of Dr Carl June.
Chief Development Officer
James joined Immunocore in December 2015 as Chief Development Officer. James has more than 25 years of experience in the pharmaceutical and biotechnology industries covering a range of development phases and therapeutic areas, including oncology. Most recently he was Chief Development Officer at Creabilis. Prior to this, James held various senior positions at Pfizer Inc., including Head of European and Asian Development Operations, Development Team Leader within the Gastrointestinal Therapeutic Area and Development Operations Oncology Therapeutic Area Head, Europe, where he supported the successful Aromacin® EU filing and approval and has led the delivery of several global drug filings. He holds an M.Phil from Imperial College London in Statistics and Operational research.
Chief HR Officer
Ken joined Immunocore as Chief HR Officer in 2016. He has over 30 years’ experience in human resources and has significant experience in implementing global HR strategies and people development programmes to support business growth across Europe, North America and AsiaPacific regions. Prior to joining Immunocore, Ken served as Global HR Director at Sophos Ltd where he was part of the senior management team and responsible for defining and translating business needs to develop human capital strategy. While at Sophos he established the HR strategy and supported the company’s growth from 700 to 2500 globally. Previously, Ken was Head of HR at Nestle Waters in Oxford. Earlier experiences include senior positions at Blackwell Publishing and RM plc. Ken has a broad range of qualifications, including in financial planning, project management, advanced sales training and systems analysis.